Jiangsu Nanfang Medical Co., Ltd.

Jiangsu Nanfang Medical Co., Ltd. faced notable stock volatility on July 17, 2026, with a significant decline. Over the past week and month, the stock has dropped considerably, while year-to-date performance shows a modest gain. Financial challenges include a high debt-to-equity ratio and a substantial net profit loss.

Jiangsu Nanfang Medical Co., Ltd. faced a notable stock decline, contrasting with the broader market's modest gain. The company reported significant financial challenges, including a substantial net profit loss and declining sales and operating profit over the past five years, reflecting a complex situation in the pharmaceuticals sector.

Jiangsu Nanfang Medical Co., Ltd. saw a notable rise in stock performance, achieving an intraday high of CNY 7.74. Over the past year, the company has outperformed the China Shanghai Composite, despite facing challenges such as declining net sales and operating profit. Its market capitalization is CNY 2,242 million.

Jiangsu Nanfang Medical Co. has seen a notable increase in stock performance, achieving a significant intraday high on June 17, 2026. Year-to-date, the company has outperformed the China Shanghai Composite, although it faces challenges such as a high debt-to-equity ratio and negative return on equity.

Jiangsu Nanfang Medical Co., Ltd. has demonstrated strong stock performance, significantly outperforming the China Shanghai Composite in various timeframes. Despite its impressive gains over the past year and three years, the company remains loss-making, with a negative return on equity and a high debt-to-equity ratio.

Jiangsu Nanfang Medical Co., Ltd. saw a notable rise in stock performance, achieving an intraday high of CNY 6.96. The company has outperformed the China Shanghai Composite index and reported a year-to-date increase, despite facing challenges such as a high debt-to-equity ratio and significant net profit loss.